[{"arm_notes": "nan", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "Cohort 1: non intubated; Progression of respiratory failure will be defined as a sustained increase in oxygen requirement or need for intubation/mechanical ventilation", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "Cohort 2: intubated; Progression of respiratory failure will be defined as a need for increasing respiratory support (e.g. FiO2 or PEEP)", "treatment_id": 1299, "treatment_name": "Tocilizumab", "treatment_type": "Interleukin inhibitors", "pharmacological_treatment": "Pharmacological treatment"}]